Age-Related Macular Degeneration Clinical Trials in Beijing
7 recruitingBeijing, China
Showing 1–7 of 7 trials
Recruiting
Phase 3
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular DegenerationnAMD
Hoffmann-La Roche68 enrolled16 locationsNCT05562947
Recruiting
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Neovascular Age-related Macular DegenerationDiabetic Macular EdemaRetinal Vein Occlusion
Hoffmann-La Roche1,000 enrolled41 locationsNCT06439576
Recruiting
Phase 3
QA108 Phase III Study in Subjects With Intermediate AMD
Intermediate Age-Related Macular Degeneration
Smilebiotek Zhuhai Limited400 enrolled1 locationNCT07189169
Recruiting
Phase 1Phase 2
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Skyline Therapeutics (US) Inc.68 enrolled9 locationsNCT05986864
Recruiting
Phase 1
A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Youxin Chen12 enrolled3 locationsNCT06213038
Recruiting
Phase 1Phase 2
Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Age-Related Macular Degeneration
Chengdu Origen Biotechnology Co., Ltd.42 enrolled1 locationNCT05672121
Recruiting
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
Neovascular (Wet) Age-related Macular Degeneration
Skyline Therapeutics83 enrolled10 locationsNCT06346600